Ms. Tanisha Manoj Arte | Nanotechnology | Best Researcher Award

Mercer University – Atlanta, GA | United States

Tanisha Manoj Arte is an emerging pharmaceutical researcher specializing in non-invasive vaccine delivery systems, microparticulate formulation, and immunological assay development. Her research focuses on advancing next-generation vaccine technologies by developing and optimizing multi-route delivery platforms such as intranasal, buccal, and transdermal systems. She has contributed significantly to the design of microparticle-based vaccines targeting SARS-CoV-2 variants and influenza viruses, emphasizing heterologous prime-boost strategies for cross-protective immunity. Tanisha’s collaborative work with institutions such as Inventprise Inc., Vaxine Pty Ltd., and Emory University reflects her interdisciplinary approach integrating formulation science, nanotechnology, and immunotherapy. Her expertise encompasses spray drying, microfluidic synthesis, and analytical characterization of nano- and microparticles, coupled with in vivo and in vitro immunological assessments. Tanisha’s scientific contributions have been published in high-impact journals such as International Journal of Pharmaceutics, Pharmaceutics, Vaccines, and Viruses, where her research demonstrates innovative approaches toward pain-free and thermally stable vaccine formulations. She has also explored 3D-printed drug delivery platforms for therapeutic applications, such as curcumin-based vaginal films and buccal films for viral vaccines. Her work exemplifies innovation in translational biopharmaceutics and contributes to global efforts in improving vaccine accessibility and efficacy. Tanisha has received recognition as a recipient of the Best Researcher Award for her impactful contributions to non-invasive vaccine research. Her publications collectively demonstrate over 120 citations, with an h-index of 6 on Scopus and h-index of 8 on Google Scholar, highlighting her growing influence in the field of pharmaceutical sciences.

Publication Profile

Orcid

Featured Publications

• Arte, T. M., Patil, S. R., Adediran, E., Singh, R., Bagwe, P., Gulani, M. A., Pasupuleti, D., Ferguson, A., Zughaier, S. M., & D’Souza, M. J. (2025). Microneedle delivery of heterologous microparticulate COVID-19 vaccine induces cross-strain specific antibody levels in mice. Vaccines, 13(4), 380.

• Singh, R., Gulani, M., Vijayanand, S., Arte, T., Adediran, E., Pasupuleti, D., Patel, P., Ferguson, A., Uddin, M., & Zughaier, S. M. (2025). An intranasal quadruple variant vaccine approach using SARS-CoV-2 and influenza A: Delta, Omicron, H1N1 and H3N2. International Journal of Pharmaceutics, 126043.

• Adediran, E., Arte, T., Pasupuleti, D., Vijayanand, S., Singh, R., Patel, P., Gulani, M., Ferguson, A., Uddin, M., & Zughaier, S. M. (2025). Delivery of PLGA-loaded influenza vaccine microparticles using dissolving microneedles induces a robust immune response. Pharmaceutics, 17(4), 510.

• Shah, S., Patel, P., Ferguson, A., Bagwe, P., Kale, A., Adediran, E., Singh, R., Arte, T., Pasupuleti, D., & Uddin, M. (2024). Buccal administration of a Zika virus vaccine utilizing 3D-printed oral dissolving films in a mouse model. Vaccines, 12(7), 720.

• Shah, S., Patel, P., Bagwe, P., Kale, A., Ferguson, A., Adediran, E., Arte, T., Singh, R., Uddin, M. N., & D’Souza, M. J. (2024). Intranasal immunization for Zika in a pre-clinical model. Viruses, 16(6), 865.